Criteria for judging the immune markers of COVID-19 disease vaccines

被引:0
作者
Lin, Nan [1 ]
Fu, Haoxuan [2 ]
Pu, Dan [3 ]
Quan, Yuxin [1 ]
Li, Yueyi [4 ]
Yin, Xiaomeng [4 ]
Wei, Yuhao [1 ]
Wang, Hang [1 ]
Ma, Xuelei [4 ]
Wei, Xiawei [5 ]
机构
[1] Sichuan Univ, West China Hosp, West China Sch Med, Chengdu, Peoples R China
[2] Univ Illinois, Dept Stat, Urbana, IL USA
[3] Sichuan Univ, West China Hosp, Canc Ctr, Dept Radiat Oncol, Chengdu, Peoples R China
[4] Sichuan Univ, West China Hosp, Canc Ctr, Dept Biotherapy, Chengdu, Peoples R China
[5] Sichuan Univ, West China Hosp, Natl Clin Res Ctr Geriatr, Lab Aging Res & Nanotoxicol,State Key Lab Biother, Chengdu, Peoples R China
来源
MEDCOMM | 2022年 / 3卷 / 01期
关键词
assessment; neutralizing antibodies; SARS-CoV-2; vaccine; NCOV-19; AZD1222; VACCINE; INACTIVATED VACCINE; INTERIM ANALYSIS; EFFICACY; IMMUNOGENICITY; SARS-COV-2; SAFETY; INFECTION; ANTIBODY; BLIND;
D O I
10.1002/mco2.109
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sweeping the world, effective and affordable vaccines are in urgent need. A reliable system for the assessment of SARS-CoV-2 vaccines would boost the development of vaccines and reduce the research cost. We constructed a logistic regression model and analyzed the relationship between antibody (Ab) level and efficacy of different vaccine types. The relationship between assessment dates and Ab levels was depicted by plotting the mean of Ab levels evolved over time and a fitted cubic polynomial model. Anti-spike immunoglobulin G (IgG) could best estimate the vaccine efficacy (VE) (adjusted R-2( )= 0.731) and neutralizing Ab to live SARS-CoV-2 also explained a fine relationship (adjusted R-2 = 0.577). Neutralizing Abs to live SARS-CoV-2 in inactivated virus vaccines reached a peak during days 40-60, and their receptor-binding domain (RBD)-IgG peaked during days 40-50. For messenger RNA (mRNA) and viral vector vaccines, their neutralizing Ab to live SARS-CoV-2 peaked later than day 40, and for RBD-IgG during days 30-50. For mRNA and viral vector vaccines, their peak time of Abs was later than that in inactivated virus vaccines. RBD-IgG peaked earlier than Ab to live SARS-CoV-2. Anti-spike IgG and Ab to live SARS-CoV-2 may be good immune markers for VE assessment.
引用
收藏
页数:12
相关论文
共 61 条
  • [1] Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate
    Addetia, Amin
    Crawford, Katharine H. D.
    Dingens, Adam
    Zhu, Haiying
    Roychoudhury, Pavitra
    Huang, Meei-Li
    Jerome, Keith R.
    Bloom, Jesse D.
    Greninger, Alexander L.
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2020, 58 (11)
  • [2] Agha Mounzer, 2021, medRxiv, DOI 10.1101/2021.04.06.21254949
  • [3] Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults A Randomized Clinical Trial
    Al Kaabi, Nawal
    Zhang, Yuntao
    Xia, Shengli
    Yang, Yunkai
    Al Qahtani, Manaf M.
    Abdulrazzaq, Najiba
    Al Nusair, Majed
    Hassany, Mohamed
    Jawad, Jaleela S.
    Abdalla, Jehad
    Hussein, Salah Eldin
    Al Mazrouei, Shamma K.
    Al Karam, Maysoon
    Li, Xinguo
    Yang, Xuqin
    Wang, Wei
    Lai, Bonan
    Chen, Wei
    Huang, Shihe
    Wang, Qian
    Yang, Tian
    Liu, Yang
    Ma, Rui
    Hussain, Zaidoon M.
    Khan, Tehmina
    Saifuddin Fasihuddin, Mohammed
    You, Wangyang
    Xie, Zhiqiang
    Zhao, Yuxiu
    Jiang, Zhiwei
    Zhao, Guoqing
    Zhang, Yanbo
    Mahmoud, Sally
    ElTantawy, Islam
    Xiao, Peng
    Koshy, Ashish
    Zaher, Walid Abbas
    Wang, Hui
    Duan, Kai
    Pan, An
    Yang, Xiaoming
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 326 (01): : 35 - 45
  • [4] Aleman A., 2021, FATAL BREAKTHROUGH I, DOI [10.1101/2021.05.15.21256814, DOI 10.1101/2021.05.15.21256814]
  • [5] Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents
    Ali, Kashif
    Berman, Gary
    Zhou, Honghong
    Deng, Weiping
    Faughnan, Veronica
    Coronado-Voges, Maria
    Ding, Baoyu
    Dooley, Jacqueline
    Girard, Bethany
    Hillebrand, William
    Pajon, Rolando
    Miller, Jacqueline M.
    Leav, Brett
    McPhee, Roderick
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (24) : 2241 - 2251
  • [6] Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
    Anderson, E. J.
    Rouphael, N. G.
    Widge, A. T.
    Jackson, L. A.
    Roberts, P. C.
    Makhene, M.
    Chappell, J. D.
    Denison, M. R.
    Stevens, L. J.
    Pruijssers, A. J.
    McDermott, A. B.
    Flach, B.
    Lin, B. C.
    Doria-Rose, N. A.
    O'Dell, S.
    Schmidt, S. D.
    Corbett, K. S.
    Swanson, P. A., II
    Padilla, M.
    Neuzil, K. M.
    Bennett, H.
    Leav, B.
    Makowski, M.
    Albert, J.
    Cross, K.
    Edara, V. V.
    Floyd, K.
    Suthar, M. S.
    Martinez, D. R.
    Baric, R.
    Buchanan, W.
    Luke, C. J.
    Phadke, V. K.
    Rostad, C. A.
    Ledgerwood, J. E.
    Graham, B. S.
    Beigel, J. H.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (25) : 2427 - 2438
  • [7] Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
    Baden, Lindsey R.
    El Sahly, Hana M.
    Essink, Brandon
    Kotloff, Karen
    Frey, Sharon
    Novak, Rick
    Diemert, David
    Spector, Stephen A.
    Rouphael, Nadine
    Creech, C. Buddy
    McGettigan, John
    Khetan, Shishir
    Segall, Nathan
    Solis, Joel
    Brosz, Adam
    Fierro, Carlos
    Schwartz, Howard
    Neuzil, Kathleen
    Corey, Larry
    Gilbert, Peter
    Janes, Holly
    Follmann, Dean
    Marovich, Mary
    Mascola, John
    Polakowski, Laura
    Ledgerwood, Julie
    Graham, Barney S.
    Bennett, Hamilton
    Pajon, Rolando
    Knightly, Conor
    Leav, Brett
    Deng, Weiping
    Zhou, Honghong
    Han, Shu
    Ivarsson, Melanie
    Miller, Jacqueline
    Zaks, Tal
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (05) : 403 - 416
  • [8] Covid-19 Breakthrough Infections in Vaccinated Health Care Workers
    Bergwerk, Moriah
    Gonen, Tal
    Lustig, Yaniv
    Amit, Sharon
    Lipsitch, Marc
    Cohen, Carmit
    Mandelboim, Michal
    Gal Levin, Einav
    Rubin, Carmit
    Indenbaum, Victoria
    Tal, Ilana
    Zavitan, Malka
    Zuckerman, Neta
    Bar-Chaim, Adina
    Kreiss, Yitshak
    Regev-Yochay, Gili
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (16) : 1474 - 1484
  • [9] Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial
    Borobia, Alberto M.
    Carcas, Antonio J.
    Perez-Olmeda, Mayte
    Castano, Luis
    Jesus Bertran, Maria
    Garcia-Perez, Javier
    Campins, Magdalena
    Portoles, Antonio
    Gonzalez-Perez, Maria
    Garcia Morales, Maria Teresa
    Arana-Arri, Eunate
    Aldea, Marta
    Diez-Fuertes, Francisco
    Fuentes, Inmaculada
    Ascaso, Ana
    Lora, David
    Imaz-Ayo, Natale
    Baron-Mira, Lourdes E.
    Agusti, Antonia
    Perez-Ingidua, Carla
    Gomez de la Camara, Agustin
    Ramon Arribas, Jose
    Ochando, Jordi
    Alcami, Jose
    Belda-Iniesta, Cristobal
    Frias, Jesus
    [J]. LANCET, 2021, 398 (10295) : 121 - 130
  • [10] Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients
    Boyarsky, Brian J.
    Werbel, William A.
    Avery, Robin K.
    Tobian, Aaron A. R.
    Massie, Allan B.
    Segev, Dorry L.
    Garonzik-Wang, Jacqueline M.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 325 (17): : 1784 - 1786